论文部分内容阅读
为探讨rasP~(21)在喉癌及癌前病变的表达及其在喉癌的发生、发展中的作用,我们应用免疫组化S—P法对30例喉癌、20例正常喉粘膜(对照组)及14例喉粘膜非典型增生的石蜡切片进行了标记,结果P~(21)蛋白在喉癌的表达)为86.7%,比正常喉粘膜(无1例表达)有明显差异;喉粘膜上皮非典型增生的P~(21)蛋白的表达率为64.3%,亦比正常喉粘膜有明显差异,但与喉癌相比,其P~(21)表达无明显差异(P<0.05);而喉粘膜上皮非典型增生与喉癌各分级之间的差别有极其显著的意义(P<0.1)。显示rasP~(21)的表达强度随肿瘤的恶性程度增高而增强。提示P~(21)表达增强可望成为喉癌前病变发生癌变的重要指标之一。
To investigate the expression of rasP ~ (21) in laryngeal carcinoma and precancerous lesions and its role in the occurrence and development of laryngeal carcinoma, we used immunohistochemical S-P method in 30 cases of laryngeal carcinoma and 20 cases of normal laryngeal mucosa Control group) and 14 cases of atypical laryngeal mucosa paraffin sections were labeled, the results of P 21 protein expression in laryngeal cancer) was 86.7%, compared with normal laryngeal mucosa (no expression) were significantly different; throat The expression of P21 in mucosal epithelial dysplasia was 64.3%, which was also significantly different from that in normal laryngeal mucosa. However, there was no significant difference in the expression of P21 in laryngeal carcinoma (P <0.05) (P <0.01). However, there was a significant difference between atypical hyperplasia of laryngeal mucosa and each grade of laryngeal carcinoma (P <0.1). It showed that the expression intensity of rasP ~ (21) increased with the malignant degree of the tumor. Tip P ~ (21) enhanced expression is expected to become a precancerous lesions of the an important indicator of cancer.